Venous thromboembolism (VTE) is the third leading cause of death among cardiovascular diseases and poses a significant danger, especially for hospitalised patients. The global influence of DVT on health is a further consideration that must be acknowledged. The prevalence of deep vein thrombosis (DVT) is increasing, and venous thromboembolism (VTE) remains a significant worldwide health issue. This further substantiates that timely diagnosis and efficient treatment are essential. Deep vein thrombosis (DVT) is the result of around two-thirds of venous thromboembolism (VTE) cases, while PE is the primary symptom of the remaining one-third.   Although DVT is usually associated with hospitalised patients, over two-thirds of cases actually occur in outpatient settings. Heredity, advanced age, hypercoagulable diseases (like cancer), and temporary situations (like medication, bed rest, hospitalisation, travel, and trauma) are among the factors that raise the risk of blood clots. When many variables interact and may have a cumulative effect, the likelihood of mortality may increase.  Despite intensive attempts to identify and quantify DVT dangers, a substantial fraction of DVT cases—up to 20%—are classified as idiopathic, meaning no discernible risk factor has been identified.   Because of this, DVT is an extremely difficult disease to predict and prevent. The management of deep vein thrombosis (DVT) is predominantly based on personalised approaches. The patient's profile, clinical condition, and risk factors must guide the formulation of a care strategy. Specific patient groups may get advantages from interventional techniques such as mechanical thrombectomy, catheter-directed thrombolysis (CDT), and anticoagulant therapy. CDT intervention involves assessing the costs and risks against the benefits of minimising PTS and reoccurring DVT.   Due to its long-term benefits, CDT is best for patients with IFDVT and other severe thromboses at high risk for recurrence and/or PTS, as well as those with a long life expectancy and minimal comorbidities. Three medical associations advocate CDT for DVT.All CDT recommendations advocate using it with anticoagulation. To ascertain the efficacy and enduring consequences of these methodologies, larger patient cohorts must engage in longitudinal follow-up investigations.